| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G | Gainor Lewis Berray (Filed by) | ||
6-K | Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial | ||
6-K | Clearmind Medicine Announces $2 Million Promissory Note Financing | ||
6-K | Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets | ||
6-K | Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | ||
6-K | Clearmind Medicine Submits Recommendations to FDA Regarding Psychedelic Therapies and Non-Hallucinogenic Neuroplastogens | ||
6-K | Clearmind Medicine Inc. Announces 1-for-8 Reverse Share Split | ||
6-K | Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations | ||
6-K | Clearmind Medicine Testifies at Historic FDA Psychedelic Hearing on Patient Access and Neuroplastogens | ||
6-K | Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial | ||
6-K | Clearmind Medicine Inc. Condensed Interim Consolidated Financial Statements for the Three and Nine Months Ended July 31, 2026 | ||
6-K | Clearmind Medicine Receives Yale IRB Approval for CMND-100 Phase I/II Trial |
